UNITED CNS is a next-generation sequencing (NGS) tissue test panel for classifying central nervous system (CNS) cancers. It meets WHO CNS5 standard-of-care in aiding in the classification of CNS cancer subtypes and grades to support accurate diagnosis and treatment.
WHO 2021 CNS Tumor Classification - Required Targets on UNITED™ CNS [1]
Available internationally outside the USA.
Downloads
Specifications [2]
Single Nucleotide Variants (SNVs)
98%
Sensitivity
100%
Specificity
Insertions / Deletions (indels)
98%
Sensitivity
100%
Specificity
Fusions
91.25%
Sensitivity
100%
Specificity
MSI-High
100%
Sensitivity
100%
Specificity
Tumor Mutational Burden
98.6%
R² Correlation to Whole Exome Sequencing
Results tested at the stated mutant allele frequencies using reference standards,
FFPE cell line samples, and FFPE clinical samples.
Sensitivity and specificity reported for SNVs and Indels are at 5% VAF.
The limit of detection for chromosomal copy number alterations is 30% tumor fraction.
References:
-
Gritsch, S. et al. Cancer 2022 128(1):47–58.
-
Ng, CC-Y. et al. Front. Mol. Biosci. 2022. 9:963243.